Introduction
Obesity, obesity, T2D, obese, ®, medicantions, impaired fasting glucose, prediabetes, overweight, metabolic syndrome
OBESITY, OBESITY, OBESE, ADVERSE EVENTS, PREDIABETES, INSULIN RESISTANCE, METABOLIC SYNDROME, INSULIN SENSITIVITY
The incidence of overweight and obesity has reached epidemic levels and represents a major serious threat to public health on a global scale [Obesity is a major risk factor for T2D and prediabetes [In the United States of America, the age-adjusted prevalence of overall obesity increased from 35.4% in 2011–2012 to 43.4% in 2017–2018 [Obesity has increased globally and at least 2.8 million people die each year from obesity or being overweight. In 2015, a total of 107.7 million children and 603.7 million adults were obese. In more than 70 countries, the prevalence of obesity has doubled since 1980, and it has increased continuously in the majority of other countries [The current explosion in T2D and obesity prevalence rates is a result of significant secular changes in lifestyle and environment which may have a tendency to cluster within families (obvious examples include foetal environment, socioeconomic status, dietary preferences, food availability, a more sedentary way of life, stress, pharmaceutical or endocrine disruptors, and a lower microbial diversity of the gut microbiota composition in obesity) [Over the next twenty years, overweight and obesity in all Latin American countries are estimated to increase [For the treatment of obesity and prediabetes, a number of medicantions have been used, including sibutramine, rimonabant, orlistat, lorcaserin, phentermine/topiramate, exenatide, liraglutide, thiazolidinediones, acarbose, and metformin, among others [The nutritional supplement Obex®, produced by Laboratorios Catalysis, has recently entered the market. It is specifically produced with natural antioxidants and helps to lose weight, with no adverse events having been reported so far. Several articles [In 2015, Medialdea et al. found that taking the Obex® supplement was beneficial for the treatment of central obesity and prevention of metabolic syndrome in climacteric women. [In an earlier exploratory study in overweight or obese subjects with impaired fasting glucose levels, consumption of Obex® achieved a reduction in several anthropometric measurements (body weight, BMI, waist circumference, waist-to-hip ratio, and conicity index) and improved fasting glucose levels and high-density lipoprotein cholesterol (HDL-c) concentrations, as well as insulin sensitivity and insulin resistance indexes [The aim of this study was to examine the efficacy and safety of Obex® treatment in combination with lifestyle changes on anthropometric, clinical, and biochemical characteristics in overweight and obese individuals.